In:
International Journal of Cancer, Wiley, Vol. 136, No. 8 ( 2015-04-15), p. 1863-1873
Abstract:
What's New? Endometrial carcinoma is usually diagnosed early, with a favorable prognosis. However, even in these early cases, the relapse rate can be as high as 20%. Thus it would be helpful to have a biomarker that could predict which tumors are likely to recur, and which patients might benefit from more aggressive treatment. In this clinical study, the authors found that a protein called annexin A2 (ANXA2) may provide just such a biomarker. Interestingly, they also found that ANXA2 is involved in the ability of endometrial carcinomas to metastasize.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2015
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8